EA201891229A1 - Eif4a-ингибирующие соединения и связанные с ними способы - Google Patents

Eif4a-ингибирующие соединения и связанные с ними способы

Info

Publication number
EA201891229A1
EA201891229A1 EA201891229A EA201891229A EA201891229A1 EA 201891229 A1 EA201891229 A1 EA 201891229A1 EA 201891229 A EA201891229 A EA 201891229A EA 201891229 A EA201891229 A EA 201891229A EA 201891229 A1 EA201891229 A1 EA 201891229A1
Authority
EA
Eurasian Patent Office
Prior art keywords
eif4a
compounds
related methods
formula
inhibiting compounds
Prior art date
Application number
EA201891229A
Other languages
English (en)
Other versions
EA037370B1 (ru
Inventor
Джастин Т. Эрнст
Зигфрид Х. Райх
Пол А. Шпренгелер
Чинх Тран
Гаррик Кеннет Пакард
Алан Синь Сян
Кристиан Нилевски
Теодор Мичелз
Original Assignee
Эффектор Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эффектор Терапьютикс, Инк. filed Critical Эффектор Терапьютикс, Инк.
Publication of EA201891229A1 publication Critical patent/EA201891229A1/ru
Publication of EA037370B1 publication Critical patent/EA037370B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к синтезу, фармацевтически приемлемым составам и применению соединений в соответствии с формулой I или их стереоизомера, таутомера или фармацевтически приемлемой соли.Для соединений формулы I X, Y, R, R, R, R, R, Rи Rимеют значения, определенные в описании. Соединения формулы I по изобретению являются ингибиторами eIF4A и находят использование в любом числе терапевтических применений, включая, но не ограничиваясь им, лечение воспаления и различных раковых образований.
EA201891229A 2015-11-25 2016-11-22 eIF4A-ИНГИБИРУЮЩИЕ СОЕДИНЕНИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ EA037370B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259828P 2015-11-25 2015-11-25
US201662334149P 2016-05-10 2016-05-10
PCT/US2016/063353 WO2017091585A1 (en) 2015-11-25 2016-11-22 Eif4-a-inhibiting compounds and methods related thereto

Publications (2)

Publication Number Publication Date
EA201891229A1 true EA201891229A1 (ru) 2018-12-28
EA037370B1 EA037370B1 (ru) 2021-03-19

Family

ID=58720397

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891229A EA037370B1 (ru) 2015-11-25 2016-11-22 eIF4A-ИНГИБИРУЮЩИЕ СОЕДИНЕНИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ

Country Status (22)

Country Link
US (5) US9957277B2 (ru)
EP (2) EP3888658B1 (ru)
JP (1) JP7105691B2 (ru)
KR (1) KR20180096644A (ru)
CN (1) CN108601788B (ru)
AU (1) AU2016359617B2 (ru)
CA (1) CA3006041A1 (ru)
CL (1) CL2018001411A1 (ru)
CO (1) CO2018006475A2 (ru)
DK (2) DK3888658T3 (ru)
EA (1) EA037370B1 (ru)
ES (1) ES2870037T3 (ru)
FI (1) FI3888658T3 (ru)
IL (1) IL259433B (ru)
MX (1) MX2018006443A (ru)
MY (1) MY196749A (ru)
PE (1) PE20181303A1 (ru)
PH (1) PH12018501073A1 (ru)
SG (2) SG10202004793YA (ru)
TW (1) TWI731899B (ru)
WO (1) WO2017091585A1 (ru)
ZA (1) ZA201804070B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
PT3229810T (pt) 2014-11-17 2020-08-27 Cellectar Biosciences Inc Análogos de éter fosfolipídico como veículos de medicamentos direcionados para o cancro
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
WO2017091627A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
JP2018536661A (ja) 2015-11-25 2018-12-13 ギリアド アポロ， エルエルシー トリアゾールａｃｃ阻害剤およびその使用
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
MX2019013148A (es) * 2017-05-04 2019-12-18 Glenmark Pharmaceuticals Sa Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.
US11576933B2 (en) 2017-05-24 2023-02-14 Effector Therapeutics Inc. Compositions and methods for an improved antitumor immune response
JP2021513963A (ja) * 2018-02-19 2021-06-03 メモリアル スローン ケタリング キャンサー センター 異常増殖性疾患を治療するための薬剤および方法
CN109503418B (zh) * 2018-12-11 2021-06-08 河北合佳医药科技集团股份有限公司 一种甲基肼的制备工艺
US20220151976A1 (en) * 2019-02-18 2022-05-19 The University Of Toledo Targeting lasp1, eif4a1, eif4b and cxc4 with modulators and combinations thereof for cancer therapy
CN109971762B (zh) * 2019-04-24 2022-12-20 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫eIF4A基因的siRNA及其应用
KR20230005175A (ko) * 2020-03-24 2023-01-09 이펙터 테라퓨틱스, 인크. Eif4a 억제제 조합물
TW202221003A (zh) * 2020-10-28 2022-06-01 大陸商上海翰森生物醫藥科技有限公司 多環類生物調節劑、其製備方法和應用
CN112574078B (zh) * 2020-12-14 2022-09-13 湖南工程学院 2-砜基-2，3-二氢-1-茚酮及其衍生物及合成方法
WO2023030687A1 (en) 2021-09-01 2023-03-09 KHR Biotec GmbH Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
AU2022340664A1 (en) 2021-09-01 2024-03-14 KHR Biotec GmbH Novel ras inhibitors
CN115448860B (zh) * 2022-09-16 2024-04-02 上海海客宜家生物科技有限公司 一种邻甲硫基苯甲腈的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10356218A1 (de) 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
WO2005092876A1 (en) 2004-03-23 2005-10-06 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
CN100418532C (zh) 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US8137509B2 (en) 2006-05-22 2012-03-20 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2457907A1 (en) 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
CA2820718A1 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
US20150087598A1 (en) * 2012-05-11 2015-03-26 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
US20160158189A1 (en) 2013-07-17 2016-06-09 Deutsches Krebsforschungszentrum Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones
WO2015075165A1 (en) 2013-11-22 2015-05-28 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto

Also Published As

Publication number Publication date
EP3380101A1 (en) 2018-10-03
EA037370B1 (ru) 2021-03-19
DK3380101T3 (da) 2021-04-26
AU2016359617B2 (en) 2022-04-14
ZA201804070B (en) 2021-10-27
MX2018006443A (es) 2019-08-01
PE20181303A1 (es) 2018-08-09
US20170145026A1 (en) 2017-05-25
US20180298017A1 (en) 2018-10-18
EP3380101A4 (en) 2019-05-22
DK3888658T3 (da) 2024-03-18
ES2870037T3 (es) 2021-10-26
US20230071483A1 (en) 2023-03-09
US11440917B2 (en) 2022-09-13
CO2018006475A2 (es) 2018-07-10
CN108601788A (zh) 2018-09-28
CN108601788B (zh) 2021-10-22
JP2019500331A (ja) 2019-01-10
EP3888658A1 (en) 2021-10-06
TW201731832A (zh) 2017-09-16
MY196749A (en) 2023-05-03
TWI731899B (zh) 2021-07-01
PH12018501073A1 (en) 2019-01-21
CA3006041A1 (en) 2017-06-01
SG11201804132UA (en) 2018-06-28
SG10202004793YA (en) 2020-06-29
CL2018001411A1 (es) 2018-11-30
EP3888658B1 (en) 2023-12-27
US9957277B2 (en) 2018-05-01
IL259433B (en) 2021-05-31
AU2016359617A1 (en) 2018-07-05
KR20180096644A (ko) 2018-08-29
IL259433A (en) 2018-07-31
JP7105691B2 (ja) 2022-07-25
EP3380101B1 (en) 2021-01-27
WO2017091585A1 (en) 2017-06-01
US20230295179A1 (en) 2023-09-21
US20200339590A1 (en) 2020-10-29
US10577378B2 (en) 2020-03-03
BR112018010235A2 (pt) 2019-03-19
FI3888658T3 (fi) 2024-03-22

Similar Documents

Publication Publication Date Title
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692470A1 (ru) Фармацевтические комбинации
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы